Helminth Glycans at the Host-Parasite Interface and Their Potential for Developing Novel Therapeutics

Myrna J.M. Bunte*, Arjen Schots, Jan E. Kammenga, Ruud H.P. Wilbers

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Helminths are parasitic worms that have successfully co-evolved with their host immune system to sustain long-term infections. Their successful parasitism is mainly facilitated by modulation of the host immune system via the release of excretory-secretory (ES) products covered with glycan motifs such as Lewis X, fucosylated LDN, phosphorylcholine and tyvelose. Evidence is accumulating that these glycans play key roles in different aspects of helminth infection including interactions with immune cells for recognition and evasion of host defences. Moreover, antigenic properties of glycans can be exploited for improving the efficacy of anti-helminthic vaccines. Here, we illustrate that glycans have the potential to open new avenues for the development of novel biopharmaceuticals and effective vaccines based on helminth glycoproteins.
Original languageEnglish
Article number807821
JournalFrontiers in Molecular Biosciences
Volume8
DOIs
Publication statusPublished - 10 Jan 2022

Keywords

  • biopharmaceuticals
  • glycans
  • helminths
  • immunomodulation
  • vaccines

Fingerprint

Dive into the research topics of 'Helminth Glycans at the Host-Parasite Interface and Their Potential for Developing Novel Therapeutics'. Together they form a unique fingerprint.

Cite this